PolyBio Launches VIPER Diagnostics Program to Combat Long COVID Challenges

PolyBio Research Foundation Unveils VIPER Program

The PolyBio Research Foundation has officially launched VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort), marking the first substantial effort to establish valid diagnostic tests for both SARS-CoV-2 persistence and other factors contributing to Long COVID. This initiative represents the foundational step in PolyBio’s broader Long COVID Cure Initiative (LCCI), which aims to convert biological discoveries into practical treatments that can be implemented in clinical settings.

Funding and Initial Steps

An initial investment of $1.35 million has been allocated to the University of California San Francisco (UCSF) to commence this crucial program. As anticipation builds, additional funding announcements are expected to follow, aimed at further supporting this initiative.

Despite the rapid advancements made in understanding Long COVID, the medical field continues to face a significant bottleneck — the absence of validated, clinically usable diagnostics. Many existing tests, while promising, are predominantly limited to academic research and lack standardization, validation, and accessibility for clinicians. This has led to challenges in conducting clinically precise trials, poor patient stratification, and inadequate therapies that do not align with the disease's biological underpinnings.

Addressing the Bottleneck

The VIPER program aims to address these critical gaps by conducting thorough, head-to-head evaluations of prevailing diagnostic methods. The goal is to determine which tests most effectively identify SARS-CoV-2 persistence and other principal mechanisms behind Long COVID. By validating these tools, the initiative hopes to enable precise patient stratification, enhance the design of clinical trials, and hasten the process of developing targeted therapies tailored to individual patient needs.

This initiative is built upon insights gained from the Long-term Impact of Infection with Novel Coronavirus (LIINC) Study at UCSF. It follows a model inspired by significant breakthroughs achieved in the realm of HIV diagnostics. Steven Deeks, MD, a Professor of Medicine at UCSF and senior researcher involved in both the LIINC and VIPER projects, expresses his commitment to this cause, stating, "Having witnessed how a single test can transform a complex disease like HIV, I'm committed to facilitating the development of tests for Long COVID. Validated diagnostics will enable smarter, more targeted trials, ultimately leading to effective treatments reaching patients more swiftly."

Urgent Need for Solutions

Support for this program has been provided by a coalition of donors, including the Pagliuca family and Greg and Mindy White, who have family members affected by Long COVID. Steve Pagliuca, Founder and CEO of PagsGroup, emphasizes the urgency of addressing Long COVID as one of the most pressing unmet medical challenges today, stating, "While scientific insights are advancing, they are yet to reach the patients who need them most. The Long COVID Cure Initiative aims to bridge this gap by systematically accelerating the journey from discovery to real-world treatment."

Greg White, a healthcare philanthropist, adds, "The VIPER program lays the diagnostic groundwork necessary to transition from scientific discovery to clinical care, facilitating smarter clinical trials and guiding us toward effective treatments that align with the biological nuances of this disease."

A Comprehensive Approach

VIPER serves as the pioneering phase of the Long COVID Cure Initiative (LCCI), which unfolds as a structured and coordinated four-step program designed to translate biological insights into tangible impacts. By effectively linking validated diagnostics with clinical trials and therapeutic development, LCCI is steadfast in its mission to deliver scalable and patient-ready solutions for the millions grappling with Long COVID.

About PolyBio Research Foundation

PolyBio Research Foundation is a 501(c)(3) nonprofit organization dedicated to advancing a comprehensive understanding of how various infections — be they viral, bacterial, or parasitic — influence chronic diseases and accelerate aging. The foundation actively fosters collaborative initiatives aimed at pinpointing, diagnosing, and treating the underlying causes of infection-related chronic illnesses.